Ron‐Patrick Cadeddu

ORCID: 0000-0003-0484-5660
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Acute Myeloid Leukemia Research
  • Multiple Myeloma Research and Treatments
  • Hematopoietic Stem Cell Transplantation
  • Mesenchymal stem cell research
  • Platelet Disorders and Treatments
  • CAR-T cell therapy research
  • Cell Adhesion Molecules Research
  • Immune Cell Function and Interaction
  • Bone and Joint Diseases
  • Blood properties and coagulation
  • Graphene and Nanomaterials Applications
  • Lymphoma Diagnosis and Treatment
  • Carbon and Quantum Dots Applications
  • Histone Deacetylase Inhibitors Research
  • Chronic Myeloid Leukemia Treatments
  • Hematological disorders and diagnostics
  • Gene expression and cancer classification
  • Sleep and Wakefulness Research
  • Immunotoxicology and immune responses
  • Glutathione Transferases and Polymorphisms
  • Immune cells in cancer
  • Myeloproliferative Neoplasms: Diagnosis and Treatment
  • NF-κB Signaling Pathways
  • Muon and positron interactions and applications
  • DNA Repair Mechanisms

Heinrich Heine University Düsseldorf
2013-2024

Düsseldorf University Hospital
2010-2024

Integrated Oncology (United States)
2024

Bipar
2017

The development of a fatal, clonal, autonomously proliferating CD4-CD8- chimeric antigen receptor (CAR)+ peripheral T-cell lymphoma (PTCL) occurred 1 month after patient received treatment with tisagenlecleucel for relapsed primary central nervous system lymphoma. PTCL had clonal rearrangement, which was already detectable in the apheresis product CAR manufacturing and 7 months earlier autologous transplantation. Somatic

10.1056/nejmoa2402730 article EN New England Journal of Medicine 2024-10-02

Graphene quantum dots (GQDs) are a promising next generation nanomaterial with manifold biomedical applications. For real world applications, comprehensive studies on their influence the functionality of primary human cells mandatory. Here, we report effects GQDs transcriptome CD34+ hematopoietic stem after an incubation time 36 hours. Of 20 800 recorded gene expressions, only one, namely selenoprotein W, 1, is changed by in direct comparison to cultivated without GQDs. Only meta analysis...

10.1038/s41598-019-48567-6 article EN cc-by Scientific Reports 2019-08-19

Bleeding complications are a significant clinical problem in patients with myelodysplastic syndromes even at sufficient platelet counts (>50,000/μl). However, the underlying pathology of this hemorrhagic diathesis is still unknown. Here, we analyzed proteome by quantitative two-dimensional difference gel electrophoresis followed mass spectrometric protein identification. Proteins identified lower concentrations, such as Talin-1, Vinculin, Myosin-9, Filmain-A, and Actin play critical roles...

10.1074/mcp.m112.023168 article EN cc-by Molecular & Cellular Proteomics 2013-02-05

Human leukocytes obtained from samples of leukapheresis products three healthy donors stimulated by granulocyte colony stimulating factor (G-CSF) were exposed to graphene quantum dots.

10.1039/c6ra27829a article EN cc-by-nc RSC Advances 2017-01-01

Azacitidine (Aza) combined with donor lymphocyte infusions (DLI) is an established treatment for relapse of myeloid malignancies after allogeneic transplantation. Based on its immunomodulatory and anti-leukemic properties we considered Lenalidomide (Lena) to act synergistically Aza/DLI improve outcome. We, therefore, prospectively investigated tolerability efficacy this combination as first salvage therapy adults post-transplant acute leukemia, myelodysplastic syndromes chronic...

10.3324/haematol.2022.282570 article EN cc-by-nc Haematologica 2023-06-01

Acute myeloid leukemia (AML) is characterized by an expansion of leukemic cells and a simultaneous reduction normal hematopoietic precursors in the bone marrow (BM) resulting insufficiency, but underlying mechanisms are poorly understood humans. Assuming that functionally inhibit healthy CD34+ stem progenitor (HSPC) via humoral factors, we exposed BM-derived HSPC to cell-free supernatants derived from AML cell lines as well 24 newly diagnosed patients. Exposure AML-derived significantly...

10.1002/stem.3387 article EN cc-by-nc-nd Stem Cells 2021-05-20

Phthalates are a group of synthetic plasticizers that ubiquitous environmental pollutants with toxic and endocrine disrupting characteristics. DEHP is the most commonly used plasticizer in world still applied to stem cell transfusion bags for storage hematopoietic progenitor cells (CD34+ HSPC), which transferred during transplantation. Here we examined effect on vitality CD34+ HSPC as well specific properties like migration differentiation capacity - both important successful...

10.3233/ch-151984 article EN Clinical Hemorheology and Microcirculation 2015-09-09

There is a variety of antineoplastic drugs that are based on natural compounds from ecological niches with high evolutionary pressure. We used two cell lines (Jurkat J16 and Ramos) in screening to assess 300 different naturally occurring regard their activity. The results the 4,6-dibromo-2-(2′,4′-dibromophenoxy)phenol (P01F03), 4,5,6-tribromo-2-(2′,4′-dibromophenoxy)phenol (P01F08), 5-epi-nakijinone Q (P03F03) prompted us perform further research. Using viability apoptosis assays primary...

10.3390/md17090521 article EN cc-by Marine Drugs 2019-09-05

Little data are available for the expression of immune checkpoint (IC) molecules within myelodysplastic syndrome (MDS). Here, we report increased PD-L1+ CD34+ CD38- and CD38+ stem cell frequencies MDS patients compared to recipients in remission. Additionally, observed exceedingly similar PD1+ Tim-3+ T-cell between acute myeloid leukaemia (AML) samples that were elevated Furthermore, found highly dynamic serial relapsing with excess blasts (MDS-EB II) patients, correlating further disease...

10.1111/bjh.17461 article EN British Journal of Haematology 2021-05-06

Using multi-color flow cytometry analysis, we studied the immunophenotypical differences between leukemic blasts/LSCs from patients with AML/MDS and hematopoietic stem progenitor cells (HSPCs) in complete remission (CR) following their successful treatment. The panel of markers included CD34, CD38, CD45RA, CD123 as representatives for a hierarchical cell (HSPC) classification well programmed death ligand 1 (PD-L1). Rather than restricting evaluation on 2- or 3-dimensional applied...

10.20944/preprints202403.0042.v1 preprint EN 2024-03-04

Softeners like phthalate esters are ubiquitous in the environment and have been detected transfusion bags, though there is only a limited amount of studies on effect phthalates blood cells. This study seeks to determine effects cell migration human promyelocytic leukemia cells (HL-60) incubated with di(2-ethylhexyl)phthalate (DEHP) at concentrations found bags.HL-60 were DEHP ranging from 0.1 μg/ml 1000 μg/ml, diluted DMSO, over 24 h, 48 72 h. Migration rate was analyzed along an SDF-1α...

10.3233/ch-141903 article EN Clinical Hemorheology and Microcirculation 2014-01-01

Using multi-color flow cytometry analysis, we studied the immunophenotypical differences between leukemic cells from patients with AML/MDS and hematopoietic stem progenitor (HSPCs) in complete remission (CR) following their successful treatment. The panel of markers included CD34, CD38, CD45RA, CD123 as representatives for a hierarchical cell (HSPC) classification well programmed death ligand 1 (PD-L1). Rather than restricting evaluation on 2- or 3-dimensional applied t-distributed...

10.3390/cancers16071320 article EN Cancers 2024-03-28

New drugs for the treatment of multiple myeloma (MM) comprise immunomodulatory substances such as lenalidomide and related compounds. While has found its way into first‐line well relapse therapy, little is known about effects on normal hematopoietic stem progenitor cells (HSPCs). In this study, we investigated whether HSPCs are influenced by a phenotypic, functional gene expression level. For that purpose, samples from patients with MM were obtained who underwent equivalent including...

10.1002/ijc.30257 article EN International Journal of Cancer 2016-07-07
Coming Soon ...